Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invested in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The Company's portfolio consists of pharmaceutical products with molecules and includes both in-licensed products, such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome as well as products owned (or partially owned) by it, such as Exelon and Impavido.


TSX:GUD - Post by User

Bullboard Posts
Comment by porksnifferon Feb 01, 2019 9:48am
85 Views
Post# 29305270

RE:RE:RE:RE:Globe and Mail Spotlight

RE:RE:RE:RE:Globe and Mail Spotlight
2j3kl wrote: Surely a great story of human survival against very high odds .

But, he is obviously not at full capability .
His largest investment has not produced the products that were envisaged.
Those Funds could be sufficient to acquire Cipher and bring back Mark who is currently CEO of Cipher, formerly of Endo and before that was co- developer of Paladin.

It would take the strain of Goodie while bringing 15 more products into our product suite.

Lets get the price up to $12 and use equity as part of the Cipher deal..



I personally see nothing positive or flattering fron that article other than a great survival story. It is clear he is not at full capacity and admits it. This has been a disaster of an investment for most shareholders. So at this point why is he still in the head position in the company? Why not do the honourable thing and step down and let someone else run it? Makes zero sense to me.
Bullboard Posts